Clinical Trial Update: Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on personalized CAPTEM radiopeptide therapy for advanced, non-resectable neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• CAPTEM (CAPTEM)

Snippet

Sponsor: University of Warmia and Mazury | Conditions: Neuroendocrine Tumors | Phase 2 | Status: UNKNOWN